What is MGTX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.03B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MGTX?

P/E (TTM) is 13.00 and 52-week range is $6.62 to $15.35 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MGTX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MGTX?

The company profile lists revenue (TTM) near $392M, net income (TTM) near $78M, EPS (TTM) near $0.71 when available from the market-data feed. Figures are informational and may lag live markets.

Where is MeiraGTx Holdings PLC based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 92.6M shares outstanding, ISIN KYG596651029 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

MeiraGTx Holdings PLC

$MGTX

Health Care · Biotechnology

IR Run Scenarios

$10.69

+1.81%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

MeiraGTx Holdings Plc is a clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. The company has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. The company is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.

Employees

400

Website

meiragtx.com/

IPO

2018-06-08

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)